Enovis CORP
No enriched coverage for $ENOV in the last 7 days.
No SEC Form 4 filings for $ENOV in the last 30 days.
See all $ENOV insider activity →Needham reduced its price target for Enovis Corp (NYSE:ENOV) to $34 from $52, citing margin pressure from the expected acquisition of eCential Robotics. The firm maintained a Buy rating and adjusted 2027 EBITDA and EPS estimates downward. Enovis shares trade near their 52-week low, with analysts noting a potential undervaluation.
Needham reaffirmed its Buy rating on Enovis with a $34 price target, suggesting a 92.2% upside from the Oct 9 close. The firm expects Enovis to see accelerating revenue growth, driven by higher-margin products, particularly in its Prevention & Recovery segment. The company is also projected to achieve adjusted EPS growth exceeding revenue growth, supported by margin improvements.
STAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.
Recent ENOV coverage spans financial news, insider activity and earnings.
Target cut signals expected margin compression and earnings pressure.
Analyst reaffirmation and higher price target may lift the stock.
Weak guidance and a miss on full‑year EPS expectations triggered a steep decline, indicating bearish sentiment.
Analyst downgrade suggests downside pressure on ENOV.
Delayed data could affect confidence in the ankle replacement product line.
AlphAI scores every news story that mentions ENOV with an AI model for sentiment and relevance, and aggregates insider trades from Enovis CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Needham reduced its price target for Enovis Corp (NYSE:ENOV) to $34 from $52, citing margin pressure from the expected acquisition of eCential Robotics. The firm maintained a Buy rating and adjusted 2027 EBITDA and EPS estimates downward. Enovis shares trade near their 52-week low, with analysts noting a potential undervaluation.
2 min readNeedham reaffirmed its Buy rating on Enovis with a $34 price target, suggesting a 92.2% upside from the Oct 9 close. The firm expects Enovis to see accelerating revenue growth, driven by higher-margin products, particularly in its Prevention & Recovery segment. The company is also projected to achieve adjusted EPS growth exceeding revenue growth, supported by margin improvements.
1 min readSTAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.
4 min readUBS reduced its price target for Enovis Corp (NYSE:ENOV) to $44 from $51, citing the impact of its recent acquisition and seasonality. The stock is trading at $18.43, near its 52-week low, with a potential upside of over 138% to the new target. Enovis expects a 100 basis points headwind to 2027 adjusted EBITDA margins due to the acquisition, with margin improvement anticipated in 2028.
2 min readThe FDA often approves drugs with postmarket safety studies, but many are delayed. Tavneos, a drug by Amgen, is one example with delays and reported liver damage cases. KFF Health News found hundreds of delayed studies, raising concerns about patient safety and wasted resources. The FDA defends its approach, citing legitimate reasons for delays. Companies like Pfizer and Amgen are working to complete their studies. The delays can leave patients and doctors uncertain about risks and benefits.
2 min readConifer Management bought $40.6M of Group 1 Automotive (GPI) shares, while directors of Alpha Metallurgical (AMR), GameStop (GME), Tyson Foods (TSN), and Enovis (ENOV) made notable purchases. Silver Lake sold $47.2M of Dell (DELL) shares, with Dell trading near its 52-week high. Gratitude 2022 Trust sold $32M of AGNT shares, which are near a 52-week low.
2 min readEngert Oliver (Chief Administrative Officer) purchased 2,660 shares of Enovis CORP (ENOV) at $18.80 on 2026-09-04.
1 min readEnovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.
3 min readEngert Oliver (Chief Administrative Officer) purchased 7,598 shares of Enovis CORP (ENOV) at an average of $19.74 ($19.46–$20.32, $0.15M total) across 2 trades over 2026-09-02 to 2026-09-03.
1 min readMcDonald Damien (Chief Executive Officer) purchased 13,035 shares of Enovis CORP (ENOV) at $19.15 ($0.25M total) on 2026-09-04.
1 min read
